Aortic valve replacement is a cardiac surgery procedure whereby a failing aortic valve is replaced with an artificial heart valve. The aortic valve may need to be replaced because of aortic regurgitation (back flow), or if the valve is narrowed by stenosis.
Current methods for aortic valve replacement include open-heart surgery, minimally invasive cardiac surgery (MICS), surgical aortic valve replacement (SAVR), percutaneous or transcatheter aortic valve replacement (TAVR; also PAVR, PAVI, TAVI), and robotic aortic valve replacement (RAVR).
A cardiologist can evaluate whether a heart valve repair or valve replacement would be of benefit.
History
During the late 1940s and early 1950s, the first surgical approaches towards treating aortic valve stenosis had limited success. The first attempts were valvotomies, (i.e. cutting the valve while the heart is pumping). A ball valve prosthesis placed on the descending thoracic aorta (heterotopically) was developed by Hufnagel, Harvey and others to address aortic stenosis, but had disastrous complications. Later, with the innovation of cardiopulmonary bypass, the ball valve prosthesis was placed orthotopically (i.e. in same place as the original aortic valve). This first generation of prosthetic valves was durable, but needed intense anti-coagulation, and cardiac hemodynamics were compromised. During the mid-1950s, a single-leaflet prosthesis was developed by Bahnson, et al. In early 1960, Ross and Barratt-Boyes used allografts. Tissue prosthetic valves were introduced in 1965 by Binet in Paris, but they degenerated quickly because the tissue was insufficiently preserved. Carpentier solved this problem by introducing glutaraldehyde-preserved stent-mounted porcine valves. The first combined robotic aortic valve replacement (RAVR) and coronary artery bypass grafting (CABG) was performed on October 31, 2024. Cardiothoracic surgeon Vinay Badhwar of West Virginia University Heart and Vascular Institute succeeded through a single small incision, using a da Vinci Xi robot.
Anatomy, physiology and pathophysiology
{| class="wikitable floatright"
|+Classification of aortic stenosis severity
|-
! U/S findings !! Mild !! Moderate !! Severe
|-
| Aortic valve area, cm<sup>2</sup>|| >1.5 || 1.0-1.5 || <1.0
|-
| Aortic valve area index, cm<sup>2</sup>/m<sup>2</sup>|| - || - || 0.6
|-
| Mean pressure gradient, mmHg || 25 || 25-40 || >40
|-
| Peak jet velocity, m/s || <3 || 3-4 || >4
|}
{| class="wikitable floatright"
|+Classification of aortic regurgitation severity
|-
! U/S findings !! Mild !! Moderate !! Severe
|-
| Jet width <br /><small>of left ventricular outflow tract</small> || <25% || 25–65% || >65%
|-
| Vena contracta width, cm || <0.3 || 0.3–0.6 || 0.6
|-
| Regurgitant volume, mL per beat || <30 || 30–49 || 60
|-
| Regurgitant fraction, % || 30 || 30–49 || >50
|-
| Regurgitant orifice area, cm<sup>2</sup>|| <0.10 || 0.10–0.30 || >0.30
|}
The aortic valve is one of the two semilunar valves of the heart with three cusps, or leaflets. It separates the heart from the aorta. Each cusp is attached to the aortic wall creating a sinus called an aortic sinus. The origins of the two coronary arteries are sited in two aortic sinuses. Cusps also known as leaflets are separated by commissures. The posterior leaflet is in continuation with the anterior leaflet of the mitral valve (the tissue is called the aorto-mitral curtain). The aortic valve is opened during systole, the driving force for it to open is the difference in pressure between the contracting left ventricle of the heart and the aorta. During cardiac diastole (when the heart chamber gets bigger) the aortic valve closes.
Aortic stenosis most commonly is the result of calcification of the cusps. Other reasons for stenosis are the bicuspid valve (some patients have only two cusps at the aortic valve instead of the usual three) and rheumatic aortic stenosis (now rare in the West). Obstruction at the level of the aortic valve causes increased pressure within the heart's left ventricle. This can lead to hypertrophy and ultimately dysfunction of the heart. While x-ray and ECG might indicate aortic stenosis, echocardiography is the diagnostic procedure of choice. US findings also help in grading the severity of the disease. In cases of symptomatic severe aortic stenosis, AVR is warranted. In cases of asymptomatic but severe aortic stenosis, more factors should be taken into consideration.
Aortic regurgitation, on the other hand, has many causes: degeneration of the cusps, endocarditis, bicuspid aortic valve, aortic root dilatation, trauma, connective tissue disorders such as Marfan syndrome or Ehlers-Danlos lead to imperfect closure of the valve during diastole, hence the blood is returning from the aorta towards the left ventricle of the heart. Acute aortic regurgitation (caused by endocarditis, aortic dissection or trauma) ends up in pulmonary edema, because of the acute increase in left ventricle (LVEDP) that does not have time to adjust to the regurgitation. Chronic regurgitation, by contrast, gives the heart time to change shape, resulting in eccentric hypertrophy, which has disastrous effects on the myocardium. Ultrasound is here also the best diagnostic mobility, either it is transthoracic or transesophageal.
Indications for surgery
Guidelines for aortic valve replacement
As long-term data on the survival and quality of life of people following valve replacement have become available, evidence-based guidelines for aortic valve replacement have been developed. These help healthcare professionals decide when aortic valve replacement is the best option for a patient. Two widely accepted sets of guidelines used by surgeons and cardiologists are the American Heart Association and American College of Cardiology Guidelines for the Management of Patients with Valvular Heart Disease, and the European Society of Cardiology and the European Association for Cardio‑Thoracic Surgery Guidelines for the management of valvular heart disease.
Aortic stenosis
Aortic stenosis is treated with aortic valve replacement in order to avoid angina, syncope, or congestive heart failure. Individuals with severe aortic stenosis are candidates for aortic valve replacement once they develop symptoms or when their heart function is impacted. Some people with asymptomatic aortic stenosis may also be candidates for aortic valve replacement, especially if symptoms appear during exercise testing. Aortic valve replacement is indicated for symptoms such as shortness of breath, and in cases where the heart has begun to enlarge (dilate) from pumping the increased volume of blood that leaks back through the valve.
Tissue valves
Tissue heart valves are usually made from animal tissue (heterografts) mounted on a metal or polymer support. Bovine (cow) tissue is most commonly used, but some are made from porcine (pig) tissue. The tissue is treated to prevent rejection and calcification (where calcium builds up on the replacement valve and stops it working properly).
Occasionally, alternatives to animal tissue valves are used: aortic homografts and pulmonary autografts. An aortic homograft is an aortic valve from a human donor, retrieved either after their death or from their heart if they are undergoing a heart transplant. A pulmonary autograft, also known as the Ross procedure is where the aortic valve is removed and replaced with the patient's own pulmonary valve (the valve between the right ventricle and the pulmonary artery). A pulmonary homograft (a pulmonary valve taken from a cadaver) is then used to replace the patient's own pulmonary valve. This procedure was first performed in 1967 and is used primarily in children, as it allows the patient's own pulmonary valve (now in the aortic position) to grow with the child. However, they tend to deteriorate more quickly in younger patients. New ways of preserving the tissue for longer are being investigated. One such preservation treatment is now being used in a commercially available tissue heart valve. In sheep and rabbit studies, the tissue (called RESILIA tissue) had less calcification than control tissue.<!--<sup>[29] [30]</sup>--> Mid-term data on the safety and haemodynamic performance of the Inspiris RESILIA aortic bioprosthesis are encouraging.<!--<sup>[31]</sup>-->
Stented and stentless tissue valves are available. Stented valves come in sizes from 19 mm to 29 mm. Stentless valves are directly sutured at the aortic root. The major advantage of stentless valves is that they limit patient–prosthesis mismatch (when the area of the prosthetic valve is too small in relation to the size of the patient, increasing the pressure inside the valve) and can be helpful when dealing with small aortic root. However, stentless valves take more time than stented valves to implant.
Mechanical valves
Mechanical valves are made from synthetic materials, such as titanium or pyrolytic carbon. Their durability is long life, while tissue valves can last for up to 15–20 years. The choice of prosthetic valve should be individualized, carefully considering each patient's unique circumstances. In that context, the new generation aortic mechanical valve (On-X) offers a potential lifetime solution without need for a repeat operation, while minimizing the risks of long-term anticoagulation due to reduced anticoagulation target INR of 1.5 to 2.0.
Valve selection
Valve choice is a balance between the lower durability of tissue valves and the increased risk of blood clots and bleeding with mechanical valves. Guidelines suggest that patient age, lifestyle and medical history should all be considered when choosing a valve. Tissue valves deteriorate more rapidly in young patients and during pregnancy, but they are preferable for women who wish to have children because pregnancy increases the risk of blood clots. Typically, a mechanical valve is considered for patients under 60 years old, while a tissue valve is considered for patients over the age of 65 years.
Recovery from aortic valve replacement takes about three months if the patient is in good health. Patients are advised not to lift anything heavier than 10 lbs for several weeks, and not to do any heavy lifting for 4–6 months after surgery to avoid damaging their breastbone. Often patients will be referred to participate in cardiopulmonary rehabilitation, which optimizes recovery and physical function in patients with recent cardiac surgeries. This can be done in an outpatient setting.
Outcomes
Surgery usually relieves the aortic disease symptoms that led the patient to the operating room. The survival curve of patients who undergo aortic valve replacements is slightly inferior to the curve of their corresponding healthy same-aged same sex population. Pre-operative severe left ventricular hypertrophy is a contributing factor to morbidity.
The risk of dying as a result of aortic valve replacement is estimated at 1–3%. Combining aortic valve replacement with coronary artery bypass grafting increases the risk of mortality. Using this approach, the surgeon replaces the valve through a smaller chest incision (6–10 cm) than that for a median sternotomy. MICS typically requires shorter recovery times, and produces less visible scarring. Alternatively, aortic valve replacement can be performed with right minithoracotomy approach via the 2nd or 3rd intercostal space. There is growing evidence that this approach can reduce postoperative morbidity allowing less blood loss, less pain,
faster recovery, and a shorter hospital stay with no difference in mortality. This approach can be particularly valuable in higher risk and elderly patients.
Transcatheter aortic valve replacement
Another alternative for many high-risk or elderly patients is transcatheter aortic valve replacement (TAVR, also known as TAVI, transcatheter aortic valve implantation). Rather than removing the existing valve, the new valve is pushed through it in a collapsed state. It is delivered to the site of the existing valve through a tube called a catheter, which may be inserted through the femoral artery in the thigh (transfemoral approach), or using a small incision in the chest and then through a large artery or the tip of the left ventricle (transapical approach). Fluoroscopy and transthoracic echocardiogram (TTE) are visual aids used to guide the process. Once the collapsed replacement valve is in place it is expanded, pushing the old valve's leaflets out of the way.
Guidelines suggest TAVR for most patients aged 75 years and older, and surgical aortic valve replacement for most younger patients. Ultimately, the choice of treatment is based on many factors.
Systematic reviews have addressed this comparison:
- "In patients with severe aortic stenosis and coronary artery disease, TAVR + PCI was associated with greater all-cause mortality at follow-up compared with SAVR + CABG."